Suppr超能文献

危重病:黏菌素与血管活性药物的联合效应:一项初步研究。

Critical-Illness: Combined Effects of Colistin and Vasoactive Drugs: A Pilot Study.

作者信息

Stamatiou Rodopi, Vasilaki Anna, Tzini Dimitra, Tsolaki Vasiliki, Zacharouli Konstantina, Ioannou Maria, Fotakopoulos George, Sgantzos Markos, Makris Demosthenes

机构信息

Physiology Laboratory, Faculty of Medicine, University of Thessaly, Biopolis, 41500 Larissa, Greece.

Laboratory of Pharmacology, Faculty of Medicine, School of Health Sciences, University of Thessaly, Biopolis, 41221 Larissa, Greece.

出版信息

Antibiotics (Basel). 2023 Jun 15;12(6):1057. doi: 10.3390/antibiotics12061057.

Abstract

Colistin is often used as a last resort for treating multidrug-resistant infections, particularly in critically ill patients in intensive care units. Nonetheless, its side effects, including myopathy, require careful monitoring. Vasoconstrictive drugs are also used in intensive care to increase blood pressure and improve blood flow to vital organs, which can be compromised in critically ill patients. The exact mechanism of colistin-induced muscle toxicity is of significant interest due to its potential intensive-care clinical implications. Colistin alone or in combination with vasoconstrictive agents was administrated in non-septic and LPS-induced septic animals for 10 days. Histopathological evaluation of the gastrocnemius muscle and dot-blot protein tissue analysis were performed. Increased intramuscular area, de-organization of the muscle fibers and signs of myopathy were observed in colistin-treated animals. This effect was ameliorated in the presence of vasoconstrictive drugs. Administration of colistin to septic animals resulted in a decrease of AMPK and cyclin-D1 levels, while it had no effect on caspase 3 levels. Vasoconstrictive drugs' administration reversed the effects of colistin on AMPK and cyclin D1 levels. Colistin's effects on muscle depend on septic state and vasoconstriction presence, highlighting the need to consider these factors when administering it in critically ill patients.

摘要

黏菌素通常被用作治疗多重耐药感染的最后手段,尤其是在重症监护病房的重症患者中。尽管如此,其副作用,包括肌病,仍需要仔细监测。血管收缩药物也用于重症监护,以提高血压并改善流向重要器官的血流,而重症患者的这些器官功能可能会受到损害。由于黏菌素诱导的肌肉毒性具有潜在的重症监护临床意义,其确切机制备受关注。在非脓毒症和脂多糖诱导的脓毒症动物中单独或联合血管收缩剂给予黏菌素10天。对腓肠肌进行组织病理学评估并进行斑点印迹蛋白质组织分析。在接受黏菌素治疗的动物中观察到肌内面积增加、肌纤维排列紊乱和肌病迹象。在存在血管收缩药物的情况下,这种效应得到改善。给脓毒症动物施用黏菌素导致AMPK和细胞周期蛋白D1水平降低,而对caspase 3水平没有影响。血管收缩药物的施用逆转了黏菌素对AMPK和细胞周期蛋白D1水平的影响。黏菌素对肌肉的影响取决于脓毒症状态和血管收缩的存在,这突出了在重症患者中施用黏菌素时考虑这些因素的必要性。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2240/10294943/0acbdd9031d6/antibiotics-12-01057-g001.jpg

相似文献

1
Critical-Illness: Combined Effects of Colistin and Vasoactive Drugs: A Pilot Study.
Antibiotics (Basel). 2023 Jun 15;12(6):1057. doi: 10.3390/antibiotics12061057.
2
Colistin Effects on Emphysematous Lung in an LPS-Sepsis Model.
Antibiotics (Basel). 2023 Dec 14;12(12):1731. doi: 10.3390/antibiotics12121731.
4
Intravenous colistin for multidrug-resistant gram-negative infections in critically ill pediatric patients.
Pediatr Crit Care Med. 2013 Jul;14(6):e268-72. doi: 10.1097/PCC.0b013e31828a740f.
5
6
Dexmedetomidine may reduce the risk of acute kidney injury development in critically ill patients during colistin therapy.
J Infect Chemother. 2023 Jul;29(7):673-677. doi: 10.1016/j.jiac.2023.03.009. Epub 2023 Mar 14.
7
Use of Colistin in Critically Ill Patients.
Adv Exp Med Biol. 2019;1145:155-179. doi: 10.1007/978-3-030-16373-0_12.

引用本文的文献

1
Risk Estimation of Deep Venous Thrombosis in Polytrauma Patients with Traumatic Brain Injury: A Nomogram Approach.
Risk Manag Healthc Policy. 2024 Dec 18;17:3187-3196. doi: 10.2147/RMHP.S487375. eCollection 2024.
2
Colistin Effects on Emphysematous Lung in an LPS-Sepsis Model.
Antibiotics (Basel). 2023 Dec 14;12(12):1731. doi: 10.3390/antibiotics12121731.

本文引用的文献

1
AMP-activated protein kinase: An energy sensor and survival mechanism in the reinstatement of metabolic homeostasis.
Exp Cell Res. 2023 Jul 1;428(1):113614. doi: 10.1016/j.yexcr.2023.113614. Epub 2023 Apr 29.
2
Neuromuscular Blockade in the Pre- and COVID-19 ARDS Patients.
J Pers Med. 2022 Sep 19;12(9):1538. doi: 10.3390/jpm12091538.
3
Delineation of the molecular mechanisms underlying Colistin-mediated toxicity using metabolomic and transcriptomic analyses.
Toxicol Appl Pharmacol. 2022 Mar 15;439:115928. doi: 10.1016/j.taap.2022.115928. Epub 2022 Feb 19.
4
Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis.
Lancet. 2022 Feb 12;399(10325):629-655. doi: 10.1016/S0140-6736(21)02724-0. Epub 2022 Jan 19.
6
Highly accurate protein structure prediction with AlphaFold.
Nature. 2021 Aug;596(7873):583-589. doi: 10.1038/s41586-021-03819-2. Epub 2021 Jul 15.
7
Rescuing the Last-Line Polymyxins: Achievements and Challenges.
Pharmacol Rev. 2021 Apr;73(2):679-728. doi: 10.1124/pharmrev.120.000020.
9
Colistin and its role in the Era of antibiotic resistance: an extended review (2000-2019).
Emerg Microbes Infect. 2020 Dec;9(1):868-885. doi: 10.1080/22221751.2020.1754133.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验